Senses Disorder TRIZ Cases

1-Heteroalkyl derivatives of 4-benzoylpiperdines target T-type calcium ion channels to reduce pain while minimizing CNS disturbances and cardiac arrhythmias.

Gene therapy modifies rod sensitivity to compensate for lost cone function in macular degeneration.

Supercharged proteins deliver Myc and Notch modulators to inner ear cells, enabling postnatal hair cell regeneration despite prior supporting cell depletion.

Triazine-oxadiazoles selectively block Nav1.7 channels, improving analgesic efficacy while minimizing side effects from off-target activity.

Aqueous cyclosporin formulation uses phospholipids and nonionic surfactants to create unilamellar liposomes for pulmonary delivery.

A corticosteroid and insulin analog formulation stimulates osteogenesis and chondrogenesis.

scCLCH1 linkers reduce steric hindrance between protein payloads and Fc domains, increasing bioactivity and circulating half-life.

Allosteric heterocyclic compounds inhibit protein kinases without competing with ATP, maintaining efficacy in high-concentration environments.

Transducing somatic cells with specific genes creates stratified epithelial tissue for wound regeneration.

Novel fused ring compound integrates angiotensin II receptor antagonism and PPARγ agonism into a single molecular structure.

Engineering antibodies with oligomannose-type N-glycans enhances ADCC activity by increasing binding affinity for FcγRIIIA receptors.

A nucleic acid aptamer with a UAACR1N1R2GGGG sequence and stem-loop structure binds chymase.

Receptor-targeted carrier particles improve bioavailability across ocular and nasal barriers while reducing systemic side effects.

A CR2-FH fusion protein delivers Factor H to complement activation sites via specific receptor binding.

Dihydrothienopyrimidine compounds modulate gamma-secretase activity to treat neurodegenerative conditions.

A bispecific antibody-drug conjugate targets PDGFR-β receptors to internalize chemotherapeutic payloads into pathological cells.

Iota-carrageenan reduces TNF-alpha production to treat type I allergies without corticosteroid side effects.

Teprotumumab blocks IGF-1R signaling to lower proptosis and clinical activity scores, avoiding relapses common with conventional immunosuppressive therapies.

Bilberry extract composition addresses limited treatment options by inhibiting auditory cell apoptosis and increasing hair cell numbers.

Soft corticosteroid compounds utilize hydrolytically labile ester linkages to deliver potent local anti-inflammatory activity.

Slurry washing purifies atropine sulfate to enhance low-concentration ophthalmic preparation stability.

Antibodies targeting second extracellular loop inhibit C5a binding, resolving limited N-terminal antagonist effectiveness.

Stimulating toll-like receptors 3 and 7 inhibits ocular angiogenesis, preventing fragile blood vessel growth behind the macula.

Imidazolone phenylalanine derivatives bind VLA-4 integrins to block leukocyte adhesion, reducing tissue damage in inflammatory disorders.

Incubated platelet-rich plasma increases viscosity to prolong contact with inner ear nerve cells, addressing ineffective conventional treatments.

Parthenogenetic stem cell lines inherit donor HLA alleles to minimize immune rejection while avoiding complex donor matching procedures.

Neutralizing Lipocalin 2 with monoclonal antibodies reduces inflammasome activation in retinal cells, addressing the lack of dry AMD treatments.

A synergistic macular carotenoid formulation increases pigment density and foveal thickness.

Temperature-responsive gels sustain antimicrobial release in the ear, preventing drainage and reducing systemic toxicity.

Axenic C. elegans homogenate selectively downregulates Th1-mediated autoimmune responses without parasitic infection risks.

Pyridyl analogue compounds improve metabolic stability and in vivo potency to treat allergic asthma.

Self-assembling peptide hydrogels create durable corneal shields that accelerate healing while reducing treatment frequency.

A multi-module polypeptide integrates Fc receptor binding and complement control protein modules to inhibit activation pathways.

Glycosylated polypeptides resolve the contradiction between receptor affinity and short blood half-life by adding sugar chains to specific amino acids.

Humanizing the antibody constant regions reduces immunogenicity while maintaining VEGF binding affinity through consensus CDR design.

Engineered AAV44.9 capsids deliver synthetic RS1 transgenes to photoreceptors, resolving inflammatory responses and limited transduction efficiency.

L-aspartic acid beta-hydroxamate inhibits VEGF production to treat choroidal neovascularization.

Segmented antibody assays distinguish free IL-18 from complexes, resolving specificity limits in inflammatory disease diagnosis.

An anti-IL-6 monoclonal antibody fused with VEGF binding domains creates a dual inhibitor molecule.

A metal oxide hollow nanosphere grafted with poly-L-histidine moves ophthalmic drugs across the cornea.

MET peptides inhibit FAS-mediated apoptosis pathways, preserving photoreceptor survival after retinal detachment.

Converting the monohydrochloride to a dihydrochloride anhydride eliminates moisture absorption and paste formation, ensuring stable crystalline storage.

Novel 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives act as potent modulators of the FPRL-1 receptor.

Facial application of topical progesterone resolves dry eye irritation and systemic exposure risks via transdermal delivery.

Colloidal silver particles stabilize botulinum toxin to extend muscle relaxation duration from 10 weeks to 24 weeks and reduce injection frequency.

Formula I bicyclic heteroaryls target PI3Kδ activity while sparing other isoforms, resolving non-specific inhibition issues in autoimmune therapy.